Drug Profile
Research programme: antibody therapeutics - AvantGen / Tanabe Research Laboratories
Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator AvantGen
- Class Antibodies; Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 04 Jan 2018 AvantGen signs licensing agreement with Tanabe Research Laboratories to generate therapeutic antibody drug candidates for cancer
- 04 Jan 2018 Early research in Cancer in USA (Parenteral)